Drug resistance as a biochemical target in cancer chemotherapy:
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
San Diego u.a.
Acad. Press
1992
|
| Schriftenreihe: | Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia
13 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXV, 342 S. graph. Darst. |
| ISBN: | 0127022953 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV004780431 | ||
| 003 | DE-604 | ||
| 005 | 19920818 | ||
| 007 | t | ||
| 008 | 920326s1992 d||| |||| 10||| engod | ||
| 020 | |a 0127022953 |9 0-12-702295-3 | ||
| 035 | |a (OCoLC)24106706 | ||
| 035 | |a (DE-599)BVBBV004780431 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-12 | ||
| 050 | 0 | |a RC271.C5 | |
| 082 | 0 | |a 616.99/4061 |2 20 | |
| 245 | 1 | 0 | |a Drug resistance as a biochemical target in cancer chemotherapy |c ed. by Takashi Tsuruo ... |
| 264 | 1 | |a San Diego u.a. |b Acad. Press |c 1992 | |
| 300 | |a XXV, 342 S. |b graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia |v 13 | |
| 650 | 2 | |a Antinéoplasiques - Pharmacologie | |
| 650 | 2 | |a Glycoprotéines - Pharmacologie | |
| 650 | 2 | |a Résistance aux médicaments | |
| 650 | 2 | |a Tumeurs - Traitement médicamenteux | |
| 650 | 4 | |a Antineoplastic Agents |x pharmacology |v Congresses | |
| 650 | 4 | |a Cancer |x Chemotherapy |x Complications |v Congresses | |
| 650 | 4 | |a Drug Resistance |v Congresses | |
| 650 | 4 | |a Drug resistance in cancer cells |v Congresses | |
| 650 | 4 | |a Glycoproteins |x pharmacology |v Congresses | |
| 650 | 4 | |a Multidrug resistance |v Congresses | |
| 650 | 4 | |a Neoplasms |x drug therapy |v Congresses | |
| 650 | 4 | |a P-glycoprotein |v Congresses | |
| 650 | 0 | 7 | |a Cytostatikum |0 (DE-588)4068347-3 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 1990 |z Tokio |2 gnd-content | |
| 689 | 0 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 0 | 1 | |a Cytostatikum |0 (DE-588)4068347-3 |D s |
| 689 | 0 | 2 | |a Arzneimittelresistenz |0 (DE-588)4143180-7 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Tsuruo, Takashi |e Sonstige |4 oth | |
| 830 | 0 | |a Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia |v 13 |w (DE-604)BV005467821 |9 13 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002942169&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-002942169 | ||
Datensatz im Suchindex
| _version_ | 1804118895794061312 |
|---|---|
| adam_text | DRUG RESISTANCE AS A BIOCHEMICAL TARGET IN CANCER CHEMOTHERAPY EDITED BY
**;;.:; ^ 4 TAKASHI INSTITUTE OF APPLIED I THE UNIVERSITY OF TOKYO * J^
I YAYOI BUNKYO, TOKYO AND R * * CANCER CHEMOTHERAPY CENTER JAPANESE
FOUNDATION FOR CANCER RESEARCH TOSHIMA, TOKYO JAPAN MAKOTO OGAWA
DIVISION OF CLINICAL CHEMOTHERAPY CANCER CHEMOTHERAPY CENTER JAPANESE
FOUNDATION FOR CANCER RESEARCH TOSHIMA, TOKYO JAPAN ACADEMIC PRESS, INC.
HARCOURT BRACE JOVANOVICH, PUBLISHERS SAN DIEGO NEW YORK BOSTON LONDON
SYDNEY TOKYO TORONTO CONTENTS 1 CONTRIBUTORS XIII EDITOR S FOREWORD XXI
FOREWORD XXIII PREFACE XXV INTRODUCTION TO THE BRISTOL-MYERS SQUIBB DRUG
RESISTANCE IN CANCER SYMPOSIUM GREGORY A. CURT TEXT 1 REFERENCES 6 PART
I GENETIC ASPECTS OF MULTIDRUG RESISTANCE THE P-GLYCOPROTEIN GENE FAMILY
P. BORST, F. BAAS, C. R. LINCKE, M. OUELLETTE, A. H. SCHINKEL, AND J. J.
M. SMIT I. INTRODUCTION 11 II. P-GLYCOPROTEIN GENES IN UNICELLULAR
EUKARYOTES 12 III. P-GLYCOPROTEIN GENES IN SIMPLE MULTICELLULAR
EUKARYOTES 15 IV. THE P-GLYCOPROTEIN GENES OF MAMMALS 16 V. THE HUMAN
MDR3/2 GENE 20 VI. OUTLOOK 21 REFERENCES 23 CONTENTS MOLECULAR GENETIC
ANALYSIS OF P-GLYCOPROTEIN FUNCTION AND EXPRESSION IN HUMAN CELLS I. B.
RONINSON, K. E. NOONAN, K. CHOI, B. S. MORSE, C.-J. * CHEN, J. CHIN, R.
KAPLAN STERN, AND A. R. SAFA I. INTRODUCTION 28 II. HUMAN MDR GENES:
STRUCTURE AND EXPRESSION 29 III. THE ROLE OF THE MDR1 GENE IN MULTIDRUG
RESISTANCE 32 IV. STRUCTURAL AND MUTATIONAL ANALYSIS OF P- GLYCOPROTEIN
FUNCTION 34 V. DIAGNOSTICS OF MDR1 EXPRESSION IN HUMAN CANCER BY
POLYMERASE CHAIN REACTION 38 REFERENCES 40 FUNCTION OF THE MULTIDRUG
TRANSPORTER MICHAEL M. GOTTESMAN, MASARU HORIO, ISABELLE LELONG, JOSEPH
HANDLER, YOSSEF RAVIV, HANAN GALSKI, GERALD MICKISCH, GLENN MERLINO,
MARK C. WILLINGHAM, AND IRA PASTAN I. INTRODUCTION 46 II. THE
LOCALIZATION OF P-GLYCOPROTEIN IN NORMAL TISSUES SUGGESTS A ROLE IN
TRANSEPITHELIAL TRANSPORT 47 III. MODEL SYSTEMS IN WHICH P-GLYCOPROTEIN
ACTS AS AN ENERGY-DEPENDENT DRUG TRANSPORTER 49 IV. MULTIDRUG TRANSPORT
MAY INVOLVE EXTRACTION OF HYDROPHOBIC DRUGS FROM LIPID BILAYERS 52 V.
TRANSGENIC MICE EXPRESSING THE MDR1 GENE IN BONE MARROW 57 VI.
CONCLUSIONS 59 REFERENCES 60 A COMPARISON OF THE STRUCTURE, FUNCTION,
AND EXPRESSION OF P-GLYCOPROTEINS ENCODED BY MDRIA IN MDRIB IN MOUSE LEE
M. GREENBERGER, STEPHEN I.-H. HSU, CHIA-PING HUANG YANG, DALIA COHEN,
LEONARD LOTHSTEIN, EDWARD KYU-HO HAN, LAWRENCE S. KIRSCHNER, RICHARD L.
PEIKARZ, LIJIA YU, AND SUSAN BAND HORWITZ I. INTRODUCTION 64 II.
STRUCTURAL DIFFERENCES BETWEEN P- GLYCOPROTEIN FAMILY MEMBERS 69
CONTENTS VII III. FUNCTIONAL DIFFERENCES ASSOCIATED WITH MDRLA AND MDRLB
76 IV. DIFFERENCES IN EXPRESSION BETWEEN MDRLA AND MDRLB 86 V.
CONCLUSIONS 89 REFERENCES 89 PART II PROTEINS INVOLVED IN DRUG
RESISTANCE AS TARGETS FOR CANCER CHEMOTHERAPY MULTIDRUG RESISTANCE:
BASIC APPROACHES FOR REVERSAL TAKASHI TSURUO I. II. III. IV. V. VI. VII.
INTRODUCTION BASIC PROPERTIES OF THE P-GLYCOPROTEIN OF MDR CELLS
P-GLYCOPROTEIN AS A TARGET OF CANCER CHEMOTHERAPY APPLICATION OF
MONOCLONAL ANTIBODIES FOR THERAPY OF HUMAN RESISTANT CELLS SEARCH FOR
NEW AGENTS TO REVERSE DRUG * RESISTANCE DEVELOPMENT AND EVALUATION OF
NEW ANTITUMOR AGENTS EFFECTIVE AGAINST HUMAN DRUG-RESISTANT TUMORS
CONCLUSION REFERENCES 100 100 102 103 109 111 112 113 EXPRESSION OF
P-GLYCOPROTEIN ISOFORMS VICTOR LING, GRACE BRADLEY, LENA M. VEINOT,
TADAAKI . ., HIRUKI, AND ELIAS GEORGES I. INTRODUCTION 118 II.
P-GLYCOPROTEIN GENE FAMILY MEMBERS IN DIFFERENT SPECIES 119 III.
LOCALIZATION OF P-GLYCOPROTEIN ISOFORMS IN CHINESE HAMSTER 123 IV.
CONCLUDING REMARKS 126 REFERENCES 127 VIII CONTENTS 7 THE USE OF YEAST
AND YEAST STRAINS EXPRESSING HUMAN DNA TOPOISOMERASES IN THE STUDY OF
ANTICANCER DRUGS PIERO BENEDETTI, MONIKA TSAI-PFLUGFELDER, AND JAMES C.
WANG I. INTRODUCTION 130 II. DNA TOPOISOMERASES AS TARGETS OF
THERAPEUTICS 131 III. YEAST AS A GENETIC SYSTEM FOR THE STUDY OF DNA
TOPOISOMERASE-TARGETING ANTICANCER DRUGS 134 IV. EXPRESSION OF HUMAN DNA
TOPOISOMERASES I AND II IN YEAST FOR DRUG SCREENING OR FOR THE
CONSTRUCTION OF DRUG-RESISTANT MUTANT HUMAN ENZYMES 136 V. A UNIQUE
FEATURE OF TOPOISOMERASE- TARGETING DRUGS THAT INTERFERE WITH
TRANSESTERIFICATION 139 VI. POTENTIAL TARGETS FOR THE DEVELOPMENT OF NEW
THERAPEUTICS 140 VII. DRUGS OF THE SAME THEME BUT DIFFERENT COLORS 141
VIII. CONCLUDING REMARKS 142 REFERENCES 143 8 MECHANISMS OF TUMOR CELL
KILLING BY TOPOISOMERASE POISONS PETER D ARPA, ERASMUS SCHNEIDER, AND
LEROY F. LIU I. INTRODUCTION 147 II. TOPOISOMERASE I POISONS 149 III.
TOPOISOMERASE II POISONS 154 REFERENCES 161 REGULATION OF GLUTATHIONE
TRANSFERASE P GENE: IMPLICATIONS IN CARCINOGENESIS AND DRUG RESISTANCE
MASAMI MURAMATSU, AKIHIKO OKUDA, SHIGERU MORIMURA, SHIGEHIRO OSADA,
MASAYOSHI IMAGAWA, AND MASAHARU SAKAI I. INTRODUCTION 165 II. RESULTS
AND DISCUSSION 166 III. CONCLUDING REMARKS 172 REFERENCES 174 CONTENTS
IX PART III APPROACHES AGAINST CLINICAL DRUG RESISTANCE 10 CLINICAL
DETECTION AND ROLE OF DIFFERENTIATION IN MULTIDRUG RESISTANCE T. FOJO,
LMICKLEY, C. H. HERZOG, E. D. MURPHY, G-M. LAI, AND S. E. BATES I. II.
III. IV. INTRODUCTION METHODS OF P-GLYCOPROTEIN DETECTION ROLE OF
DIFFERENTIATION IN MULTIDRUG RESISTANCE USE OF P-GLYCOPROTEIN
ANTAGONISTS REFERENCES 179 180 185 187 190 11 12 DETECTION OF
MULTIDRUG-RESISTANT HUMAN CANCER CELLS BY MONOCLONAL ANTIBODIES MASANORI
SHIMOYAMA I. INTRODUCTION 194 II. SENSITIVITY AND SPECIFICITY OF
MONOCLONAL ANTIBODIES, MRK16-F(AB ) 2 AND MRK20-F(AB ) 2 194 III.
REACTIVITY OF MONOCLONAL ANTIBODIES WITH NORMAL LEUKOCYTES IN PERIPHERAL
BLOOD 203 IV. REACTIVITY OF MRK16-F(AB ) 2 AND MRK20-F(AB ) 2 WITH
CLINICAL SAMPLES 204 V. SUMMARY 207 REFERENCES 208 MOLECULAR ANALYSIS OF
HUMAN IL-2 AND IL-2 RECEPTORS TADATSUGU TANIGUCHI, MASANORI HATAKEYAMA,
SEIJIRO MINAMOTO, TAKESHI KONO, HISASHI MORI, YUTAKA OKAMOTO, AND KEIJI
SHIMIZU I. II. HI. IV. V. VI. INTRODUCTION STRUCTURE OF HUMAN IL-2
STRUCTURE OF THE IL-2 RECEPTOR COMPLEX IL-2R(J CHAIN AND SIGNAL
TRANSDUCTION IL-2RP IS FUNCTIONAL IN A NEURAL CELL LINE SUMMARY
REFERENCES 211 213 214 216 217 219 219 CONTENTS 13 14 15 THE
INTERACTIONS AMONG STEROID HORMONES, STEROID HORMONE RECEPTORS,
ANTIESTROGENS, BIOLOGICAL-RESPONSE MODIFIERS AND CYTOTOXIC DRUGS IN
HUMAN BREAST CANCER ROBERT CLARKE AND ROBERT B. DICKSON I. INTRODUCTION
224 II. EFFECTS OF BIOLOGICAL-RESPONSE MODIFIERS AND CYTOTOXIC DRUGS ON
STEROID HORMONE*RECEPTOR EXPRESSION AND RESPONSE TO ANTIESTROGENS 227
III. EFFECTS OF HORMONAL THERAPIES ON RESPONSE TO CYTOTOXIC DRUGS 232
IV. EFFECTS OF CYTOTOXIC DRUGS ON SERUM HORMONES 240 V. CONCLUSIONS 240
REFERENCES 242 PART IV CLINICAL APPROACHES AGAINST DRUG FAILURE CLINICAL
DETECTION OF MULTIDRUG RESISTANCE AND REVERSAL WITH CHEMOSENSITIZING
AGENTS SYDNEY E. SALMON, THOMAS M. GROGAN, THOMAS P. MILLER, MANFRED
LEHNERT, AND WILLIAM S. DALTON I. INTRODUCTION 257 II. CLINICAL
APPLICATIONS OF CHEMOSENSITIZERS IN CANCER THERAPY 259 III. FURTHER
STUDIES OF CHEMOSENSITIZERS 263 REFERENCES 267 CLINICAL EVALUATION OF
NON-CROSS-RESISTANT THERAPIES IN ADVANCED HODGKIN S DISEASE G.
BONADONNA, A. SANTORO, A. M. GIANNI, S. VIVIANI, L. GIANNI, AND P.
VALAGUSSA I. INTRODUCTION 271 II. RISE OF ABVD AND NON-CROSS-RESISTANT
REGIMENS 273 III. ATTEMPTS TO OVERCOME DRUG RESISTANCE BY ALTERNATING
MOPP AND ABVD 275 IV. MORE RECENT FINDINGS WITH NON*CROSS- RESISTANT
REGIMENS 278 16 XI V. ATTEMPTS TO OVERCOME DRUG RESISTANCE BY HIGH-DOSE
THERAPY 283 VI. COMMENT 285 REFERENCES 290 AUTOLOGOUS BONE MARROW
TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCY 296 296 297 299 301 301 302
GORDON L. I. II. III. IV. V. VI. PHILLIPS OVERVIEW RATIONALE CRITICAL
ISSUES CLINICAL STUDIES FUTURE DIRECTIONS CONCLUSION REFERENCES 17
DOSE-INTENSIVE THERAPY: A STRATEGY TO AVOID DRUG RESISTANCE IN SOLID
TUMORS KAREN ANTMAN I. II. III. IV. V. VI. CONSIDERATIONS IN THE DESIGN
OF A HIGH- DOSE REGIMEN FOR SOLID TUMORS BREAST CANCER BONE MARROW
TRANSPLANTATION IN BREAST CANCER BONE MARROW INVOLVEMENT SUPPORTIVE CARE
SUMMARY OF ABMT IN BREAST CANCER REFERENCES 304 306 307 310 311 313 315
18 HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE MARROW TRANSPLANTATION IN
MALIGNANT LYMPHOMAS AND BREAST CANCER MAKOTO OGAWA AND TAKETO MUKAIYAMA
I. BACKGROUND 323 II. MATERIALS AND METHODS 325 HI. RESULTS 326 IV.
DISCUSSION 328 REFERENCES 330 INDEX 333
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV004780431 |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.C5 |
| callnumber-search | RC271.C5 |
| callnumber-sort | RC 3271 C5 |
| callnumber-subject | RC - Internal Medicine |
| ctrlnum | (OCoLC)24106706 (DE-599)BVBBV004780431 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 |
| dewey-search | 616.99/4061 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02370nam a2200553 cb4500</leader><controlfield tag="001">BV004780431</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19920818 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">920326s1992 d||| |||| 10||| engod</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0127022953</subfield><subfield code="9">0-12-702295-3</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)24106706</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV004780431</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-12</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC271.C5</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4061</subfield><subfield code="2">20</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Drug resistance as a biochemical target in cancer chemotherapy</subfield><subfield code="c">ed. by Takashi Tsuruo ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">San Diego u.a.</subfield><subfield code="b">Acad. Press</subfield><subfield code="c">1992</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXV, 342 S.</subfield><subfield code="b">graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia</subfield><subfield code="v">13</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Antinéoplasiques - Pharmacologie</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Glycoprotéines - Pharmacologie</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Résistance aux médicaments</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Tumeurs - Traitement médicamenteux</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">pharmacology</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy</subfield><subfield code="x">Complications</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug Resistance</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Drug resistance in cancer cells</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Glycoproteins</subfield><subfield code="x">pharmacology</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multidrug resistance</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">P-glycoprotein</subfield><subfield code="v">Congresses</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">1990</subfield><subfield code="z">Tokio</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Arzneimittelresistenz</subfield><subfield code="0">(DE-588)4143180-7</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Tsuruo, Takashi</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia</subfield><subfield code="v">13</subfield><subfield code="w">(DE-604)BV005467821</subfield><subfield code="9">13</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002942169&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-002942169</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 1990 Tokio gnd-content |
| genre_facet | Konferenzschrift 1990 Tokio |
| id | DE-604.BV004780431 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T16:17:34Z |
| institution | BVB |
| isbn | 0127022953 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-002942169 |
| oclc_num | 24106706 |
| open_access_boolean | |
| owner | DE-12 |
| owner_facet | DE-12 |
| physical | XXV, 342 S. graph. Darst. |
| publishDate | 1992 |
| publishDateSearch | 1992 |
| publishDateSort | 1992 |
| publisher | Acad. Press |
| record_format | marc |
| series | Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia |
| series2 | Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia |
| spelling | Drug resistance as a biochemical target in cancer chemotherapy ed. by Takashi Tsuruo ... San Diego u.a. Acad. Press 1992 XXV, 342 S. graph. Darst. txt rdacontent n rdamedia nc rdacarrier Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia 13 Antinéoplasiques - Pharmacologie Glycoprotéines - Pharmacologie Résistance aux médicaments Tumeurs - Traitement médicamenteux Antineoplastic Agents pharmacology Congresses Cancer Chemotherapy Complications Congresses Drug Resistance Congresses Drug resistance in cancer cells Congresses Glycoproteins pharmacology Congresses Multidrug resistance Congresses Neoplasms drug therapy Congresses P-glycoprotein Congresses Cytostatikum (DE-588)4068347-3 gnd rswk-swf Arzneimittelresistenz (DE-588)4143180-7 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 1990 Tokio gnd-content Krebs Medizin (DE-588)4073781-0 s Cytostatikum (DE-588)4068347-3 s Arzneimittelresistenz (DE-588)4143180-7 s DE-604 Tsuruo, Takashi Sonstige oth Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia 13 (DE-604)BV005467821 13 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002942169&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Drug resistance as a biochemical target in cancer chemotherapy Bristol-Myers-Squibb Company <New York, NY>: Bristol-Myers Squibb cancer symposia Antinéoplasiques - Pharmacologie Glycoprotéines - Pharmacologie Résistance aux médicaments Tumeurs - Traitement médicamenteux Antineoplastic Agents pharmacology Congresses Cancer Chemotherapy Complications Congresses Drug Resistance Congresses Drug resistance in cancer cells Congresses Glycoproteins pharmacology Congresses Multidrug resistance Congresses Neoplasms drug therapy Congresses P-glycoprotein Congresses Cytostatikum (DE-588)4068347-3 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4068347-3 (DE-588)4143180-7 (DE-588)4073781-0 (DE-588)1071861417 |
| title | Drug resistance as a biochemical target in cancer chemotherapy |
| title_auth | Drug resistance as a biochemical target in cancer chemotherapy |
| title_exact_search | Drug resistance as a biochemical target in cancer chemotherapy |
| title_full | Drug resistance as a biochemical target in cancer chemotherapy ed. by Takashi Tsuruo ... |
| title_fullStr | Drug resistance as a biochemical target in cancer chemotherapy ed. by Takashi Tsuruo ... |
| title_full_unstemmed | Drug resistance as a biochemical target in cancer chemotherapy ed. by Takashi Tsuruo ... |
| title_short | Drug resistance as a biochemical target in cancer chemotherapy |
| title_sort | drug resistance as a biochemical target in cancer chemotherapy |
| topic | Antinéoplasiques - Pharmacologie Glycoprotéines - Pharmacologie Résistance aux médicaments Tumeurs - Traitement médicamenteux Antineoplastic Agents pharmacology Congresses Cancer Chemotherapy Complications Congresses Drug Resistance Congresses Drug resistance in cancer cells Congresses Glycoproteins pharmacology Congresses Multidrug resistance Congresses Neoplasms drug therapy Congresses P-glycoprotein Congresses Cytostatikum (DE-588)4068347-3 gnd Arzneimittelresistenz (DE-588)4143180-7 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Antinéoplasiques - Pharmacologie Glycoprotéines - Pharmacologie Résistance aux médicaments Tumeurs - Traitement médicamenteux Antineoplastic Agents pharmacology Congresses Cancer Chemotherapy Complications Congresses Drug Resistance Congresses Drug resistance in cancer cells Congresses Glycoproteins pharmacology Congresses Multidrug resistance Congresses Neoplasms drug therapy Congresses P-glycoprotein Congresses Cytostatikum Arzneimittelresistenz Krebs Medizin Konferenzschrift 1990 Tokio |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=002942169&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV005467821 |
| work_keys_str_mv | AT tsuruotakashi drugresistanceasabiochemicaltargetincancerchemotherapy |